JDQ443,tislelizumab
Novartis,Beigene
['kontrast-01', 'ko,met,01', 'jdq443', 'sclc', 'nsclc', 'novartis']
interested in the kontrast-01 update at the #asco23 metastatic #nsclc session? don't miss the first report on the discovery, preclinical characterization &amp; early clinical activity of jdq443 published in last year: #kras 
Executive Editor of Cancer Discovery @CD_AACR, published by @AACR. @BBS_Harvard/@DanaFarber alum. Native New Yorker. Views/likes/RTs are my own. She/her